A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response

ISSN: 1566-5232 (Print)
ISSN: 1875-5631 (Online)


Volume 14, 6 Issues, 2014


Download PDF Flyer




Current Gene Therapy

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 21st of 161 in Genetics & Heredity

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 5.318
5 - Year: 4.322

A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response

Author(s): Walid Touati, Thi Tran, Johanne Seguin, Monique Diry, Flinois Jean-Pierre, Claude Baillou, Geraldine Lescaille, Francois Andre, Eric Tartour, Francois M Lemoine, Philippe Beaune and Isabelle de Waziers

Affiliation: INSERM UMR-S1147, 45 rue des Saints Pères, 75006 Paris, France

Abstract

Gene-directed enzyme prodrug therapy (GDEPT) consists in targeted delivery to tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. One of the major limitations of this strategy in clinical application was the poor prodrug activation capacity of suicide gene. We built a highly efficient suicide gene capable of bioactivating the prodrug cyclophosphamide (CPA) by fusing a CYP2B6 triple mutant with NADPH cytochrome P450 reductase (CYP2B6TM-RED). Expression of this fusion gene via a recombinant lentivirus (LV) vector converted resistant human (A549) and murine (TC1) pulmonary cell lines into CPA-susceptible cell lines. We tested the efficiency of our GDEPT strategy in C57Bl/6 immunocompetent mice, using TC1 cells expressing the HPV-16 E6/E7 oncoproteins. In mice bearing tumors composed only of TC1-CYP2B6TM-RED cells, four CPA injections (140 mg/Kg once a week) completely eradicated the tumors for more than two months. Tumors having only 25% of TC1-CYP2B6TM-RED cells were also completely eradicated by five CPA injections, demonstrating a major in vivo bystander effect. Moreover, surviving mice were rechallenged with parental TC1 cells. The tumors regressed spontaneously 7 days after cell inoculation or grew more slowly than in control naive mice due to a strong immune response mediated by anti-E7CD8+T cells. These data suggest that combining the CYPB6TM-RED gene with CPA may hold promise as a highly effective treatment for solid tumors in humans


Purchase Online Rights and Permissions

Article Details

Volume: 14
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/1566523214666140424152734
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science